Approved for EXDENSUR is indicated for the add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older.. Depemokimab-ulaa is an IL-5 antagonist (humanized IgG1 kappa monoclonal antibody). Side effects, costs, interactions, manufacturer, and generic alternatives sourced from FDA labels, openFDA FAERS, and CMS…
Loading full data from Know Your Drugs Institute…